Dr. Chiang on Immunotherapy in Patient Populations for Lung Cancer

Anne Chiang, MD, PhD
Published: Monday, Feb 06, 2017



Anne Chiang, MD, PhD, professor and thoracic oncologist at Yale Cancer Center, discusses immunotherapy in specific patient populations with lung cancer.

Not all patients are going to respond to immunotherapy, explains Chiang. Right now, the patient population that has a tumor proportion score of greater than 50% will likely experience a greater benefit with immunotherapy.

For those in the 1% to 49% range, we are not sure what the right answer is, says Chiang. It is important to conduct further clinical trials in that patient population.
 
SELECTED
LANGUAGE


Anne Chiang, MD, PhD, professor and thoracic oncologist at Yale Cancer Center, discusses immunotherapy in specific patient populations with lung cancer.

Not all patients are going to respond to immunotherapy, explains Chiang. Right now, the patient population that has a tumor proportion score of greater than 50% will likely experience a greater benefit with immunotherapy.

For those in the 1% to 49% range, we are not sure what the right answer is, says Chiang. It is important to conduct further clinical trials in that patient population.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Community Practice Connections™: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for NursesJun 29, 20191.5
Publication Bottom Border
Border Publication
x